Key result
In males, the LPL H-X haplotype was associated with a protective effect against significant angiographically assessed coronary artery disease.
Why the study?
Are variants in the lipoprotein lipase (LPL) gene associated with lipid levels and angiographically assessed coronary atherosclerosis in a southern Brazilian population?
Case-Control (n=506)
Are variants in the lipoprotein lipase (LPL) gene associated with lipid levels and angiographically assessed coronary atherosclerosis in a southern Brazilian population?
The HindIII and S447X variants in the LPL gene, specifically the H-X haplotype, are associated with lower triglycerides, higher HDL cholesterol, and a protective effect against significant coronary atherosclerosis in southern Brazilian males.
Answers are grounded in this paper and cite their sources.
LPL H-X haplotype may lower CAD risk in southern Brazilian males; leaves open replication before any clinical consideration.
Lipoprotein lipase is the rate-limiting enzyme in the lipolysis of plasma triglyceride-rich lipoproteins. We studied six variants (T-93G, D9N, N291S, PvuII, HindIII and S447X) in the lipoprotein lipase (LPL) gene in 309 non-diabetic patients with angiographically assessed coronary artery disease and in 197 controls in a southern Brazilian population of European descent. The HindIII H-allele was associated with lower triglycerides (p < 0.01) and higher high-density lipoprotein cholesterol (p = 0.03) levels, and the S447X mutation was associated with lower triglyceride levels (p < 0.01) in males, but not females. No other significant lipid associations were observed. Haplotypes were derived from these two sites (HindIII/S447X), and carriers of H-S and H-X haplotypes showed lower triglycerides (p < 0.01) and increased high-density lipoprotein cholesterol (p = 0.01) levels when compared to the H+S haplotype in males. In this gender, the H-X haplotype was associated with a protective effect (OR = 0.36, 95%CI = 0.13-0.97) for significant disease (> or = 60% of luminal coronary stenosis), even controlling for other classical risk factors.
No takes yet. Share an insight, caveat, or question.
Rios et al. (2003) conducted a case-control in Coronary artery disease (n=506). LPL gene variants (H-X haplotype) vs. H+S haplotype / controls was evaluated on Significant disease (≥ 60% of luminal coronary stenosis) (OR 0.36, 95% CI 0.13-0.97). In males, the LPL H-X haplotype was associated with a protective effect against significant angiographically assessed coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: